MedPacto
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
92 Myeongdal-ro, Seocho-gu, Seoul, 06668...Phone Number
+82 269380200Website
www.medpacto.comRevenue
$6.4 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About MedPacto
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company dedicated to developing innovative therapeutics targeting cancer and autoimmune diseases. MedPacto's expertise lies in utilizing genome-based methods to identify novel targets and to develop first-in-class and best-in-class drugs. MedPacto is based in Suwon, South Korea and is a subsidiary of TheragenEtex, a KOSDAQ-listed Korean company that is a leading player in the genomics industry.Explore more
MedPacto Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MedPacto your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on MedPacto recently announced quarterly report
Product Launch: Get notified when MedPacto launches new products
Check out if MedPacto is spiking on competitors!
Click to see if MedPacto had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at MedPacto
Funding: Get notified immidiatlly once MedPacto has new funding data
Check if MedPacto has recently received funding, and reach out quickly before it becomes old news!
MedPacto, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
MedPacto is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MedPacto is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MedPacto.
MedPacto Tech Stack
A closer look at the technologies used by MedPacto
See more technologies
Most Recent Scoops
Pain Point
Project
A mid-level source in Medical & Health has indicated that the organization is planning to remediate challenges related to healthcare operations.
Clinical Systems, Office Operations
Pain Point
Project
A mid-level source in Medical & Health has indicated that the organization is planning to remediate challenges related to clinical software.
Clinical Systems, Enterprise Software, Software
Pain Point
Project
A mid-level source in Medical & Health has indicated that the organization is planning to remediate challenges related to patient data.
Clinical Systems, Data Management, Information Governance
Pain Point
Project
A mid-level source in Medical & Health has indicated that the organization is planning to remediate challenges related to remote patient monitoring (rpm).
Clinical Systems, Digital Technology, Workforce Management
Project
Request for Proposal (RFP), Clinical Systems, Information Governance
MedPacto News & Media
Urothelial Carcinoma Market is Expected to Showcase a Significant Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - MedPacto, AstraZeneca, EMD Serono, Bayer, Merck, Bristol-Myers Squibb, Inovio, Seagen, Incyte
The dynamics of the urothelial carcinoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies. LAS VEGAS,...MedPacto Hires Global Clinical Expert Timothy R. Allen as Executive Vice President
SEOUL, South Korea--(BUSINESS WIRE)-- #AntiCancerDrug--MedPacto hired global clinical expert Timothy R. Allen as EVP. Dr. Allen will be in charge of global clinical trials of Vactosertib.GenScript Signs a Strategic Partnership with the Theragen Etex and MedPACTO for Therapeutic Antibody Drug development
SINGAPORE, March 25, 2021 /PRNewswire/ -- A global leading biotech company GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) announced that the Company has entered into a strategic partnership with the Theragen Etex, a South Korea-based comprehensive pharmaceutical and biotechnology group providing outstanding genetic analysis services and progressing personalized new drug development and MedPACTO, an innovative drug discovery and development company based in South Korea commencin
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MedPacto
Sign Up For FreeTo access detailed company insights
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company dedicated to developing innovative therapeutics targeting cancer and autoimmune diseases. MedPacto's expertise lies in utilizing genome-based methods to identify novel targets and to develop first-in-class and best-in-class drugs. MedPacto is based in Suwon, South Ko... Read More
